Trade AbCellera Biologics Inc. - ABCL CFD

Add to favourite

3.89

0.26%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Key Stats

Prev. Close*	3.9
Open*	3.85
1-Year Change*	-47.83%
Day's Range*	3.85 - 3.94
52 wk Range	3.87-11.38
Average Volume (10 days)	1.50M
Average Volume (3 months)	30.87M
Market Cap	1.51B
P/E Ratio	-100.00K
Shares Outstanding	290.17M
Revenue	50.39M
EPS	-0.45
Dividend (Yield %)	N/A
Beta	-100.00K
Next Earnings Date	Feb 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	3.89	0.02	0.52%	3.87	3.94	3.79
Apr 17, 2024	3.90	-0.12	-2.99%	4.02	4.07	3.90
Apr 16, 2024	4.03	-0.04	-0.98%	4.07	4.12	4.00
Apr 15, 2024	4.16	-0.10	-2.35%	4.26	4.29	4.12
Apr 12, 2024	4.31	0.00	0.00%	4.31	4.39	4.23
Apr 11, 2024	4.36	-0.12	-2.68%	4.48	4.49	4.31
Apr 10, 2024	4.44	0.00	0.00%	4.44	4.62	4.36
Apr 9, 2024	4.69	0.26	5.87%	4.43	4.72	4.40
Apr 8, 2024	4.45	0.10	2.30%	4.35	4.51	4.29
Apr 5, 2024	4.32	0.02	0.47%	4.30	4.42	4.19
Apr 4, 2024	4.36	0.04	0.93%	4.32	4.54	4.32
Apr 3, 2024	4.35	0.12	2.84%	4.23	4.41	4.19
Apr 2, 2024	4.29	-0.06	-1.38%	4.35	4.39	4.24
Apr 1, 2024	4.42	-0.08	-1.78%	4.50	4.50	4.28
Mar 28, 2024	4.50	-0.01	-0.22%	4.51	4.62	4.46
Mar 27, 2024	4.47	0.35	8.50%	4.12	4.48	4.12
Mar 26, 2024	4.27	-0.35	-7.58%	4.62	4.65	4.25
Mar 25, 2024	4.56	0.03	0.66%	4.53	4.67	4.52
Mar 22, 2024	4.57	-0.02	-0.44%	4.59	4.67	4.53
Mar 21, 2024	4.67	-0.05	-1.06%	4.72	4.80	4.64

AbCellera Biologics Inc. Events

Time (UTC)	Country	Event
Tuesday, May 7, 2024
Time (UTC) 20:00	Country US	Event Q1 2024 Abcellera Biologics Inc Earnings Release Q1 2024 Abcellera Biologics Inc Earnings Release Forecast - Previous -
Time (UTC) 21:00	Country US	Event Q1 2024 Abcellera Biologics Inc Earnings Call Q1 2024 Abcellera Biologics Inc Earnings Call Forecast - Previous -
Friday, June 14, 2024
Time (UTC) 16:00	Country US	Event Abcellera Biologics Inc Annual Shareholders Meeting Abcellera Biologics Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 20:00	Country US	Event Q2 2024 Abcellera Biologics Inc Earnings Release Q2 2024 Abcellera Biologics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	485.424	375.203	233.155	11.6115	8.83056
Revenue	485.424	375.203	233.155	11.6115	8.83056
Total Operating Expense	268.913	170.79	80.824	15.7285	9.58317
Selling/General/Admin. Expenses, Total	66.755	48.761	15.752	4.01153	2.86219
Research & Development	107.879	62.062	29.393	10.1129	5.80252
Depreciation / Amortization	27.843	14.451	4.836	1.60408	0.91846
Operating Income	216.511	204.413	152.331	-4.11701	-0.75261
Interest Income (Expense), Net Non-Operating	12.034	-2.75	-2.818	0.13181	-0.5325
Other, Net	10.554	17.486	8.32	1.7745	1.59397
Net Income Before Taxes	239.099	219.149	157.833	-2.2107	0.30885
Net Income After Taxes	158.519	153.464	118.918	-2.2107	0.30885
Net Income Before Extra. Items	158.519	153.464	118.918	-2.2107	0.30885
Net Income	158.519	153.464	118.918	-2.2107	0.30885
Total Adjustments to Net Income				0	-0.01695
Income Available to Common Excl. Extra. Items	158.519	153.464	118.918	-2.2107	0.29191
Income Available to Common Incl. Extra. Items	158.519	153.464	118.918	-2.2107	0.29191
Diluted Net Income	158.519	153.464	118.918	-2.2107	0.29191
Diluted Weighted Average Shares	314.827	318.294	269.498	265.565	265.565
Diluted EPS Excluding Extraordinary Items	0.50351	0.48215	0.44126	-0.00832	0.0011
Dividends per Share - Common Stock Primary Issue				0	0
Diluted Normalized EPS	0.50351	0.48215	0.4516	-0.00832	0.0011
Unusual Expense (Income)			3.7
Other Operating Expenses, Total	66.436	45.516	27.143

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	10.056	12.192	21.545	101.383	45.917
Revenue	10.056	12.192	21.545	101.383	45.917
Total Operating Expense	61.445	77.066	59.323	63.648	54.313
Selling/General/Admin. Expenses, Total	19.362	18.905	15.706	16.881	17.532
Research & Development	36.473	52.647	28.245	26.582	26.685
Depreciation / Amortization	5.61	5.514	13.818	5.15	4.886
Other Operating Expenses, Total	0	0	1.554	15.035	5.21
Operating Income	-51.389	-64.874	-37.778	37.735	-8.396
Interest Income (Expense), Net Non-Operating	10.779	9.759	12.034
Other, Net	2.606	6.967	-5.668	8.852	1.51
Net Income Before Taxes	-38.004	-48.148	-31.412	46.587	-6.886
Net Income After Taxes	-30.528	-40.11	-29.893	26.624	-6.785
Net Income Before Extra. Items	-30.528	-40.11	-29.893	26.624	-6.785
Net Income	-30.528	-40.11	-29.893	26.624	-6.785
Income Available to Common Excl. Extra. Items	-30.528	-40.11	-29.893	26.624	-6.785
Income Available to Common Incl. Extra. Items	-30.528	-40.11	-29.893	26.624	-6.785
Diluted Net Income	-30.528	-40.11	-29.893	26.624	-6.785
Diluted Weighted Average Shares	288.906	287.767	286.308	315.818	284.687
Diluted EPS Excluding Extraordinary Items	-0.10567	-0.13938	-0.10441	0.0843	-0.02383
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.10567	-0.13938	-0.10441	0.0843	-0.02383

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	1025.49	929.8	813.325	12.6403	15.1622
Cash and Short Term Investments	886.485	722.977	595.019	9.67689	11.0399
Cash & Equivalents	386.535	476.142	594.116	7.55292	10.4443
Short Term Investments	499.95	246.835	0.903	2.12397	0.59558
Total Receivables, Net	103.41	174.858	212.336	2.25386	3.57203
Accounts Receivable - Trade, Net	38.593	160.576	212.336	1.15256	0.80888
Prepaid Expenses	9.064	5.293		0.70959	0.55034
Total Assets	1540.91	1318.57	1005.54	23.4881	21.4922
Property/Plant/Equipment, Total - Net	217.255	111.616	17.923	8.47994	6.32994
Property/Plant/Equipment, Total - Gross	235.73	121.442	23.509	11.6369	7.88282
Accumulated Depreciation, Total	-18.475	-9.826	-5.586	-3.15696	-1.55288
Note Receivable - Long Term			0	1.78302	0
Other Long Term Assets, Total	46.331	30.642	8.388	0.58478	0
Total Current Liabilities	118.32	120.676	103.49	7.89486	6.43338
Payable/Accrued	14.828	14.924	7.13	1.64337	1.51822
Accrued Expenses	12.037	3.652	0.675	0.41914	0
Notes Payable/Short Term Debt	0	0	0	0.38725	0
Current Port. of LT Debt/Capital Leases			0.19	2.07973	2.53135
Other Current Liabilities, Total	91.455	102.1	95.495	3.36537	2.38381
Total Liabilities	307.63	292.836	175.028	13.2359	9.88297
Total Long Term Debt	0	0	2.198	1.36314	0.91122
Long Term Debt			2.198	1.36314	0.91122
Other Liabilities, Total	156.132	134.79	43.179	3.97792	2.53837
Total Equity	1233.28	1025.73	830.508	10.2521	11.6092
Preferred Stock - Non Redeemable, Net			0	7.54585	7.55701
Common Stock	734.365	722.43	710.387	5.12175	5.07369
Additional Paid-In Capital	74.118	35.357	5.919	2.30018	1.48344
Retained Earnings (Accumulated Deficit)	426.185	267.666	114.202	-4.71563	-2.50494
Total Liabilities & Shareholders’ Equity	1540.91	1318.57	1005.54	23.4881	21.4922
Total Common Shares Outstanding	286.852	283.257	269.498	265.565	265.565
Other Current Assets, Total	25	25	5.97
Goodwill, Net	47.806	47.806	31.5
Intangibles, Net	131.502	148.392	115.153
Long Term Investments	72.522	50.313	19.247
Deferred Income Tax	33.178	37.37	26.161
Total Inventory	1.532	1.672
Other Equity, Total	-1.391	0.28

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	919.518	930.735	940.653	1025.49	1045.67
Cash and Short Term Investments	785.84	795.694	796.495	886.485	868.206
Cash & Equivalents	172.422	179.747	193.017	386.535	371.973
Total Receivables, Net	75.483	86.233	99.569	103.41	105.964
Accounts Receivable - Trade, Net	37.446	45.678	20.003	38.593	105.964
Total Inventory	1.194	1.447	1.447	1.532
Prepaid Expenses	32.001	22.361	18.142	9.064
Total Assets	1512.19	1537.17	1497.92	1540.91	1552.41
Property/Plant/Equipment, Total - Net	277.209	259.64	233.187	217.255	200.602
Property/Plant/Equipment, Total - Gross	304.239	283.847	254.52	235.73	216.339
Accumulated Depreciation, Total	-27.03	-24.207	-21.333	-18.475	-15.737
Goodwill, Net	47.806	47.806	47.806	47.806	47.806
Intangibles, Net	124.076	126.747	128.845	131.502	142.548
Long Term Investments	62.887	58.792	57.583	72.522	66.718
Other Long Term Assets, Total	80.694	113.446	89.845	46.331	49.066
Total Current Liabilities	110.239	118.905	89.591	118.32	106.052
Payable/Accrued	17.432	21.025	17.569	14.828	9.319
Accrued Expenses	11.923	9.812	7.66	12.037	28.084
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total	80.884	88.068	64.362	91.455	68.649
Total Liabilities	329.415	342.339	289.419	307.63	302.237
Total Long Term Debt	0	0	0	0	0
Long Term Debt
Deferred Income Tax	33.178	33.178	33.426	33.178	34.143
Other Liabilities, Total	185.998	190.256	166.402	156.132	162.042
Total Equity	1182.78	1194.83	1208.5	1233.28	1250.17
Common Stock	747.914	744.756	742.816	734.365	730.427
Additional Paid-In Capital	109.384	96.423	81.63	74.118	64.384
Retained Earnings (Accumulated Deficit)	326.937	355.547	386.075	426.185	456.078
Total Liabilities & Shareholders’ Equity	1512.19	1537.17	1497.92	1540.91	1552.41
Total Common Shares Outstanding	289.778	289.189	288.427	286.852	285.762
Other Equity, Total	-1.46	-1.899	-2.021	-1.391	-0.717
Other Current Assets, Total	25	25	25	25	71.499
Short Term Investments	613.418	615.947	603.478	499.95	496.233

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	158.519	153.464	118.918	-2.2107	0.30885
Cash From Operating Activities	277.36	244.584	22.69	2.69372	3.56564
Cash From Operating Activities	8.953	4.403	2.317	1.60408	0.91846
Non-Cash Items	63.287	37.001	13.539	1.32723	0.42774
Changes in Working Capital	29.825	41.672	-116.701	1.9731	1.91059
Cash From Investing Activities	-352.625	-332.247	-119.78	-5.77991	-5.30707
Capital Expenditures	-72.66	-58.452	-14.673	-3.99689	-5.30707
Other Investing Cash Flow Items, Total	-279.965	-273.795	-105.107	-1.78302	0
Cash From Financing Activities	-1.628	-3.886	683.653	0.19483	12.1857
Issuance (Retirement) of Stock, Net	2.755	4.615	598.502	0.01416	10.2056
Issuance (Retirement) of Debt, Net	-0.323	-0.951	85.151	0.18067	1.98015
Net Change in Cash	-86.492	-92.974	586.563	-2.89137	10.4443
Amortization	18.89	10.062	2.519
Deferred Taxes	-2.114	-2.018	2.098
Financing Cash Flow Items	-4.06	-7.55
Foreign Exchange Effects	-9.599	-1.425

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-40.11	158.519	188.412	161.788	168.573
Cash From Operating Activities	-44.063	277.36	246.448	373.234	100.219
Cash From Operating Activities	2.858	8.953	6.212	3.681	1.391
Amortization	2.656	18.89	7.844	5.213	2.606
Deferred Taxes		-2.114
Non-Cash Items	13.446	63.287	43.148	26.226	12.675
Changes in Working Capital	-22.913	29.825	0.832	176.326	-85.026
Cash From Investing Activities	-149.609	-352.625	-335.562	-53.568	-26.371
Capital Expenditures	-14.984	-72.66	-60.33	-45.817	-14.495
Other Investing Cash Flow Items, Total	-134.625	-279.965	-275.232	-7.751	-11.876
Cash From Financing Activities	-0.458	-1.628	-1.977	-1.958	-3.131
Financing Cash Flow Items	-0.948	-4.06	-4.06	-4.06	-5
Issuance (Retirement) of Stock, Net	0.49	2.755	2.406	2.175	1.941
Issuance (Retirement) of Debt, Net		-0.323	-0.323	-0.073	-0.072
Foreign Exchange Effects	-0.213	-9.599	-9.963	-1.411	-0.204
Net Change in Cash	-194.343	-86.492	-101.054	316.297	70.513

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AbCellera Biologics Inc. Company profile

AbCellera Biologics Inc. (ABCL) is a Canadian biotechnology company that develops antibody discovery platforms. Its full-stack, AI-powered drug discovery platform searches and analyses the database of natural immune systems to find antibodies that can be used by its partners to develop into drugs.

ABCL was established in 2012 as a spin-off from the University of British Columbia (UBC), where Dr Carl Hansen, the company’s founding CEO, was a faculty member from 2005 to 2019.

The Vancouver-based company has collaborations with drug developers ranging from large cap pharmaceuticals to small biotechnology firms. As of the earnings date of 31 December 2021, the company had 156 discovery programmes either completed, in progress or under contract with 36 partners.

As a recent example, AbCellera Biologics teamed with pharma giant Eli Lilly (LLY) to co-develop two antibody therapeutics to treat and prevent Covid-19 utilising ABCL’s technological stack.

Some of the pharmaceutical companies that partnered with ABCL in the past two years include Everest Medicines for oncology or cancer; Kodiak Sciences (KOD) for partnership in eye care, Novarties (NVS), and Gilead Sciences (GILD) for infectious disease.

AbCellera Biologics was listed as a public company and began trading on the NASDAQ stock exchnage under the ticker symbol ‘ABCL’ in December 2020 through an initial public offering (IPO). ABCL’s stock price was set at $20.

You can follow the ups and downs of the ABCL’s stock price at Capital.com. Also, stay on top of the latest AbCellera Biologics’ stock price developments with our live ABCL stock chart.

Industry:

Biotechnology & Medical Research (NEC)

2215 Yukon Street
VANCOUVER
BRITISH COLUMBIA V5Y 0A1
CA

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024